Along with its financial results for the second quarter of 2025, Merck revealed a restructuring plan to save $3 billion by ...

Merck is a strong and profitable pick meeting Benjamin Graham's criteria. Read more on why investors need to stay aware of ...

The multiyear effort comes as Merck prepares to offset revenue losses from the upcoming patent expiration of its blockbuster ...

Merck Q2 earnings beat estimates but revenue fell short. Gardasil sales dropped while Keytruda and other treatments drove ...

Global pharmaceutical company Merck (NYSE:MRK) met Wall Street’s revenue expectations in Q2 CY2025, but sales fell by 1.9% ...

Analysts estimate that Merck & Co will report an earnings per share (EPS) of $2.01. Investors in Merck & Co are eagerly ...

Merck & Co. Inc. (NYSE:MRK) shares fell over 6% in early trading Tuesday after the pharmaceutical giant reported a mixed ...

Merck did not immediately respond to a request for comment on the job cuts. The company expects the program to cost about $3 billion to implement but would lead to $3 billion in annual cost savings by ...

Merck (MRK) is cutting $3 billion from its annual expenses as it prepares for generic competition to its blockbuster cancer drug, Keytruda.

Merck & Co on Tuesday announced job and cost cuts that it said will save $3 billion a year, after it posted lower ...

According to the latest study from BCC Research, the "Oncology Diagnostics: Global Markets" is projected to increase from $77.6 billion in 2024 to $101.5 billion by 2029, at a compound annual growth ...

As Keytruda generic competition looms larger on the horizon, the company is hoping to reinvest the savings into pipeline ...